Pharmacodynamic Properties of Subcutaneous Immunoglobulin in Myasthenia Gravis: Sub-analyses From an Open-Label Trial

Pharmacodynamic Properties of Subcutaneous Immunoglobulin in Myasthenia Gravis: Sub-analyses From an Open-Label Trial

Background: We previously reported an open-label prospective trial of subcutaneous immunoglobulin (SCIg) in mild to moderate exacerbations of myasthenia gravis (MG). The effective dose of SCIg in MG and whether measured immunoglobulin G (IgG) levels correlated with measures of disease burden were no...

Full description

Bibliographic Details
Main Authors: Brendan N. Putko, Grayson Beecher, Zaeem A. Siddiqi
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-08-01
Series:Frontiers in Neurology
Subjects:
subcutaneous immunoglobulin
pharmacodynamics
myasthenia gravis
hizentra
serum level
Online Access:https://www.frontiersin.org/article/10.3389/fneur.2020.00921/full

Internet

https://www.frontiersin.org/article/10.3389/fneur.2020.00921/full

Similar Items